TrialInternational journal of cancer2018

Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.

Siker Kimbung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.